编辑推荐：针对BRAF-V600E突变型转移性结直肠癌（mCRC），FDA已批准Encorafenib联合Cetuximab和mFOLFOX6一线治疗方案；同时CheckMate 8HW ...

来自某癌症中心的研究团队针对BRAF V600E突变型转移性结直肠癌（mCRC）患者，探究了早期肿瘤退缩（ETS）和缓解深度（DpR）对 ...

“Those of us in the melanoma business have felt like we ... specifically inhibits the V600E mutant BRAF, a constitutively active kinase present in more than half of metastatic melanomas.

Jedd Wolchok, Stephen Hodi, and Antonio Ribas (from Memorial Sloan-Kettering, Dana-Farber Cancer Institute, and UCLA, respectively), will treat advanced melanoma patients who have a BRAF V600E ...

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

V600E is the most commonly encountered BRAF ... for unresectable or metastatic BRAF-positive melanoma and non-small cell lung cancer (NSCLC), and as a second-line therapy in combination with ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, Fellow of the AACR Academy, as the AACR President-Elect for 2025-2026. Flaherty will become ...

standard of care in untreated BRAF V600E-mutant metastatic colorectal cancer. Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in ...